Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)
- Conditions
- Biliary Tract Carcinoma
- Interventions
- Registration Number
- NCT04003636
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Brief Summary
This is a study of pembrolizumab plus gemcitabine/cisplatin versus placebo plus gemcitabine/cisplatin as first-line therapy in participants with advanced and/or unresectable biliary tract carcinoma. The primary hypothesis is pembrolizumab plus gemcitabine/cisplatin is superior to placebo plus gemcitabine/cisplatin with respect to overall survival (OS).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 1069
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Arm A (Pembrolizumab+Gemcitabine+Cisplatin) Gemcitabine Pembrolizumab, 200 mg, every 3 weeks (Q3W), Day 1 of each 3-week cycle for up to 35 cycles PLUS Gemcitabine, 1000 mg/m\^2, Q3W, Day 1 and Day 8 of each cycle until progressive disease or unacceptable toxicity PLUS Cisplatin, 25 mg/m\^2, Q3W, Day 1 and Day 8 of each cycle for up to 8 cycles. Arm B (Placebo+Gemcitabine+Cisplatin) Gemcitabine Placebo to Pembrolizumab, 200 mg, every 3 weeks (Q3W), Day 1 of each 3-week cycle for up to 35 cycles PLUS Gemcitabine, 1000 mg/m\^2, Q3W, Day 1 and Day 8 of each cycle until progressive disease or unacceptable toxicity PLUS Cisplatin, 25 mg/m\^2, Q3W, Day 1 and Day 8 of each cycle for up to 8 cycles. Arm B (Placebo+Gemcitabine+Cisplatin) Placebo Placebo to Pembrolizumab, 200 mg, every 3 weeks (Q3W), Day 1 of each 3-week cycle for up to 35 cycles PLUS Gemcitabine, 1000 mg/m\^2, Q3W, Day 1 and Day 8 of each cycle until progressive disease or unacceptable toxicity PLUS Cisplatin, 25 mg/m\^2, Q3W, Day 1 and Day 8 of each cycle for up to 8 cycles. Arm A (Pembrolizumab+Gemcitabine+Cisplatin) Pembrolizumab Pembrolizumab, 200 mg, every 3 weeks (Q3W), Day 1 of each 3-week cycle for up to 35 cycles PLUS Gemcitabine, 1000 mg/m\^2, Q3W, Day 1 and Day 8 of each cycle until progressive disease or unacceptable toxicity PLUS Cisplatin, 25 mg/m\^2, Q3W, Day 1 and Day 8 of each cycle for up to 8 cycles. Arm A (Pembrolizumab+Gemcitabine+Cisplatin) Cisplatin Pembrolizumab, 200 mg, every 3 weeks (Q3W), Day 1 of each 3-week cycle for up to 35 cycles PLUS Gemcitabine, 1000 mg/m\^2, Q3W, Day 1 and Day 8 of each cycle until progressive disease or unacceptable toxicity PLUS Cisplatin, 25 mg/m\^2, Q3W, Day 1 and Day 8 of each cycle for up to 8 cycles. Arm B (Placebo+Gemcitabine+Cisplatin) Cisplatin Placebo to Pembrolizumab, 200 mg, every 3 weeks (Q3W), Day 1 of each 3-week cycle for up to 35 cycles PLUS Gemcitabine, 1000 mg/m\^2, Q3W, Day 1 and Day 8 of each cycle until progressive disease or unacceptable toxicity PLUS Cisplatin, 25 mg/m\^2, Q3W, Day 1 and Day 8 of each cycle for up to 8 cycles.
- Primary Outcome Measures
Name Time Method Overall Survival (OS) Up to approximately 38 months Overall survival was defined as the time from randomization to death due to any cause.
- Secondary Outcome Measures
Name Time Method Number of Participants Who Discontinued Study Intervention Due to an Adverse Event (AE) Up to approximately 38 months An AE was defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it was considered related to the medical treatment or procedure, that occurs during the course of the study.
Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (BICR) Up to approximately 26 months PFS was defined as the time from randomization to the first documented progressive disease (PD) per RECIST 1.1 by BICR, or death due to any cause, whichever occurred first.
Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) Up to approximately 26 months ORR was defined as the percentage of participants who have a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: a ≥30% decrease in the sum of diameters \[SOD\] of target lesions) as assessed by BICR per RECIST 1.1, which was adjusted for this study to allow a maximum of 10 target lesions in total and 5 per organ.
Duration of Response (DOR) Per RECIST 1.1 as Assessed by BICR Up to approximately 38 months For participants who demonstrate a confirmed CR or PR, DOR was the time from the first documented evidence of CR or PR until disease progression or death due to any cause, whichever occurred first.
Number of Participants Who Experience One or More Adverse Events (AE) Up to approximately 38 months An adverse event (AE) was defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it was considered related to the medical treatment or procedure, that occurred during the course of the study.
Trial Locations
- Locations (185)
UCLA Hematology/Oncology - Santa Monica ( Site 0014)
🇺🇸Los Angeles, California, United States
Hartford Hospital ( Site 0057)
🇺🇸Hartford, Connecticut, United States
Winship Cancer Institute of Emory University ( Site 0013)
🇺🇸Atlanta, Georgia, United States
Hospital Universitario General de Asturias ( Site 0434)
🇪🇸Oviedo, Asturias, Spain
University of California San Diego Moores Cancer Center ( Site 0008)
🇺🇸La Jolla, California, United States
McGill University Health Centre ( Site 0179)
🇨🇦Montreal, Quebec, Canada
University Hospital Coventry and Warwickshire NHS Trust ( Site 0518)
🇬🇧Coventry, United Kingdom
Oncobio Servicos de Saude SA ( Site 0604)
🇧🇷Nova Lima, Minas Gerais, Brazil
Inonu Universitesi Medical Fakultesi ( Site 0501)
🇹🇷Malatya, Adana, Turkey
Hospital Sultan Ismail ( Site 0772)
🇲🇾Johor Bahru, Johor, Malaysia
Associacao Hospitalar Moinhos de Vento ( Site 0599)
🇧🇷Porto Alegre, Rio Grande Do Sul, Brazil
Hospital de Clinicas de Porto Alegre ( Site 0610)
🇧🇷Porto Alegre, Rio Grande Do Sul, Brazil
Hospital Nossa Senhora da Conceicao ( Site 0601)
🇧🇷Porto Alegre, Rio Grande Do Sul, Brazil
Hospital de Caridade de Ijui ( Site 0602)
🇧🇷Ijui, Rio Grande Do Sul, Brazil
Centro Medico San Roque ( Site 0579)
🇦🇷San Miguel de Tucuman, Tucuman, Argentina
Hospital Municipal de Gastroenterologia Dr. Bonorino Udaondo ( Site 0580)
🇦🇷Caba, Argentina
UZA University Hospital Antwerp ( Site 0202)
🇧🇪Edegem, Antwerpen, Belgium
900 Hospital of the Joint ( Site 0137)
🇨🇳Fuzhou, Fujian, China
West China Hospital of Sichuan University ( Site 0147)
🇨🇳Chengdu, Sichuan, China
CHU Bordeaux Haut-Leveque Centre Francois Magendie ( Site 0245)
🇫🇷Pessac Cedex, Gironde, France
A.P.H. Paris, Hopital Beaujon ( Site 0247)
🇫🇷Clichy, Hauts-de-Seine, France
CHU de Montpellier - Hopital Saint-Eloi ( Site 0248)
🇫🇷Montpellier, Herault, France
CHU Clermont-Ferrand - Site Estaing ( Site 0249)
🇫🇷Clermont-Ferrand, Puy-de-Dome, France
Gustave Roussy ( Site 0244)
🇫🇷Villejuif, Val-de-Marne, France
Universitaetsklinikum Magdeburg A.o.R. ( Site 0271)
🇩🇪Magdeburg, Sachsen-Anhalt, Germany
The First Affiliated Hospital of Xi an Jiaotong University ( Site 0145)
🇨🇳XI An, Shanxi, China
Gallipoli Medical Research Foundation ( Site 0705)
🇦🇺Brisbane, Queensland, Australia
Tom Baker Cancer Centre ( Site 0184)
🇨🇦Calgary, Alberta, Canada
Saint Francis Health System ( Site 0051)
🇺🇸Greenville, South Carolina, United States
OHSU Center for Health & Healing ( Site 0044)
🇺🇸Portland, Oregon, United States
Centro Oncologico Riojano Integral ( Site 0584)
🇦🇷La Rioja, Argentina
CHU de Liege ( Site 0201)
🇧🇪Liège, Liege, Belgium
Hospital Paulistano - Amil Clinical Research ( Site 0603)
🇧🇷Sao Paulo, Brazil
Centre Hospitalier de l Universite de Montreal - CHUM ( Site 0180)
🇨🇦Montreal, Quebec, Canada
Fujian Provincial Cancer Hospital ( Site 0154)
🇨🇳Fuzhou, Fujian, China
Hunan Cancer Hospital ( Site 0132)
🇨🇳Changsha, Hunan, China
Klinikum der Ludwig - Maximilian Universitat Munchen ( Site 0264)
🇩🇪Muenchen, Bayern, Germany
Beijing Cancer Hospital ( Site 0138)
🇨🇳Beijing, Beijing, China
Peking Union Medical College Hospital ( Site 0150)
🇨🇳Beijing, Beijing, China
Erasme Hospital ( Site 0204)
🇧🇪Bruxelles, Bruxelles-Capitale, Region De, Belgium
Real e Benemerita Associacao Portuguesa de Beneficencia ( Site 0609)
🇧🇷Sao Paulo, Brazil
Hamilton Health Sciences-Juravinski Cancer Centre ( Site 0182)
🇨🇦Hamilton, Ontario, Canada
Fundacion Favaloro ( Site 0578)
🇦🇷Ciudad de Buenos Aires, Caba, Argentina
Saint-Luc UCL ( Site 0200)
🇧🇪Brussels, Bruxelles-Capitale, Region De, Belgium
Centro Investigación del Cáncer James Lind ( Site 0622)
🇨🇱Temuco, Araucania, Chile
Sociedad Oncovida S.A. ( Site 0626)
🇨🇱Santiago, Region M. De Santiago, Chile
Anhui Provincial Hospital ( Site 0140)
🇨🇳Hefei, Anhui, China
Harbin Medical University Cancer Hospital ( Site 0133)
🇨🇳Harbin, Heilongjiang, China
Hunan Provincial People Hospital ( Site 0142)
🇨🇳Changsha, Hunan, China
The First Hospital of Jilin University ( Site 0131)
🇨🇳Chanchun, Jilin, China
Tianjin Medical University Cancer Institute & Hospital ( Site 0155)
🇨🇳Tianjin, Tianjin, China
Krankenhaus Nordwest ( Site 0266)
🇩🇪Frankfurt, Hessen, Germany
Medizinische Hochschule Hannover ( Site 0265)
🇩🇪Hannover, Niedersachsen, Germany
Cross Cancer Institute ( Site 0183)
🇨🇦Edmonton, Alberta, Canada
Zhongshan Hospital Fudan University ( Site 0129)
🇨🇳Shanghai, Shanghai, China
The First Affiliated Hospital Zhejiang University ( Site 0136)
🇨🇳Hangzhou, Zhejiang, China
The 81st Hospital of PLA ( Site 0128)
🇨🇳Nanjing, Jiangsu, China
CEMIC ( Site 0581)
🇦🇷Buenos Aires, Caba, Argentina
Western Health-Sunshine Hospital ( Site 0709)
🇦🇺St Albans, Victoria, Australia
UZ Leuven ( Site 0205)
🇧🇪Leuven, Vlaams-Brabant, Belgium
Servicios Medicos Urumed ( Site 0621)
🇨🇱Rancagua, Lbtdr Gen Bernardo O Higgins, Chile
Pontificia Universidad Catolica de Chile ( Site 0620)
🇨🇱Santiago, Region M. De Santiago, Chile
First Affiliated Hospital of The Third Military Medical University ( Site 0130)
🇨🇳Chongqing, Chongqing, China
Universitaetsklinikum Koeln ( Site 0274)
🇩🇪Koeln, Nordrhein-Westfalen, Germany
Cork University Hospital ( Site 0538)
🇮🇪Cork, Ireland
Tallaght University Hospital ( Site 0522)
🇮🇪Dublin, Ireland
Eastern Health ( Site 0704)
🇦🇺Box Hill, Victoria, Australia
ASST Grande Ospedale Metropolitano Niguarda ( Site 0332)
🇮🇹Milano, Italy
Hadassah Ein Karem - Sharett Institute of Oncology ( Site 0309)
🇮🇱Jerusalem, Israel
Tangdu Hospital ( Site 0146)
🇨🇳XI An, Shanxi, China
Azienda Ospedaliero Universitaria Pisana ( Site 0326)
🇮🇹Pisa, Italy
Kyoto University Hospital ( Site 0083)
🇯🇵Kyoto, Japan
Policlinico S. Orsola-Malpighi ( Site 0333)
🇮🇹Bologna, Italy
A.O. di Rilievo Nazionale e di alta Specializzazione Garibaldi ( Site 0330)
🇮🇹Catania, Italy
Aichi Cancer Center Hospital ( Site 0080)
🇯🇵Nagoya, Aichi, Japan
Kagawa University Hospital ( Site 0086)
🇯🇵Kita-gun, Kagawa, Japan
Chonnam National University Hwasun Hospital ( Site 0837)
🇰🇷Hwasun Gun, Jeonranamdo, Korea, Republic of
CHA Bundang Medical Center CHA University ( Site 0835)
🇰🇷Seongnam, Kyonggi-do, Korea, Republic of
Kyungpook National University Chilgok Hospital ( Site 0834)
🇰🇷Daegu, Taegu-Kwangyokshi, Korea, Republic of
Severance Hospital Yonsei University Health System ( Site 0836)
🇰🇷Seoul, Korea, Republic of
Universita Cattolica del Sacro Cuore - Policlinico Gemelli ( Site 0329)
🇮🇹Rome, Abruzzo, Italy
Kyorin University Hospital ( Site 0077)
🇯🇵Mitaka, Tokyo, Japan
Chungnam National University Hospital ( Site 0840)
🇰🇷Daejeon, Taejon-Kwangyokshi, Korea, Republic of
National Cheng Kung University Hospital ( Site 0864)
🇨🇳Tainan, Taiwan
Korea University Guro Hospital ( Site 0832)
🇰🇷Seoul, Korea, Republic of
Azienda Ospedaliera Universitaria di Verona ( Site 0334)
🇮🇹Verona, Italy
Osaka University Hospital ( Site 0085)
🇯🇵Suita, Osaka, Japan
Policlinico Universitario Campus Biomedico ( Site 0328)
🇮🇹Roma, Italy
National Hospital Organization Kyushu Cancer Center ( Site 0078)
🇯🇵Fukuoka, Japan
National Cancer Center Hospital East ( Site 0081)
🇯🇵Kashiwa, Chiba, Japan
Kobe City Medical Center General Hospital ( Site 0087)
🇯🇵Kobe, Hyogo, Japan
Baskent University Adana Training Hospital ( Site 0499)
🇹🇷Adana, Turkey
The Cancer Institute Hospital of JFCR ( Site 0082)
🇯🇵Tokyo, Japan
Asan Medical Center ( Site 0830)
🇰🇷Seoul, Korea, Republic of
Ajou University Hospital, Clinical Research Center ( Site 0838)
🇰🇷Suwon-si, Kyonggi-do, Korea, Republic of
University Malaya Medical Centre ( Site 0770)
🇲🇾Lembah Pantai, Kuala Lumpur, Malaysia
Hospital Pulau Pinang ( Site 0773)
🇲🇾Georgetown, Pulau Pinang, Malaysia
UMCG ( Site 0349)
🇳🇱Groningen, Netherlands
China Medical University Hospital ( Site 0862)
🇨🇳Taichung, Taiwan
Chang Gung Medical Foundation. Linkou ( Site 0853)
🇨🇳Taoyuan, Taiwan
Udon Thani Cancer Hospital ( Site 0886)
🇹🇭Udon Thani, Thailand
Abdurrahman Yurtaslan Onkoloji Hastanesi ( Site 0494)
🇹🇷Ankara, Turkey
Erciyes Universitesi Tip Fakultesi ( Site 0500)
🇹🇷Kayseri, Turkey
Samsung Medical Center ( Site 0831)
🇰🇷Seoul, Korea, Republic of
The Catholic University of Korea. Seoul St. Mary s Hospital ( Site 0839)
🇰🇷Seoul, Korea, Republic of
Auckland City Hospital ( Site 0725)
🇳🇿Auckland, New Zealand
King Chulalongkorn Memorial Hospital ( Site 0884)
🇹🇭Bangkok, Krung Thep Maha Nakhon, Thailand
Siriraj Hospital ( Site 0888)
🇹🇭Bangkok, Krung Thep Maha Nakhon, Thailand
Maharaj Nakorn Chiang Mai Hospital ( Site 0887)
🇹🇭Chiang Mai, Thailand
Srinagarind Hospital ( Site 0885)
🇹🇭Khon Kaen, Thailand
Sunpasithiprasong Hospital ( Site 0883)
🇹🇭Ubonratchathani, Ubon Ratchathani, Thailand
Institut Kanser Negara - National Cancer Institute ( Site 0767)
🇲🇾Putrajaya, Wilayah Persekutuan Putrajaya, Malaysia
Hospital Kuala Lumpur ( Site 0768)
🇲🇾Kuala Lumpur, Malaysia
Universitair Medisch Centrum Utrecht ( Site 0351)
🇳🇱Utrecht, Netherlands
Royal Marsden NHS Foundation Trust ( Site 0535)
🇬🇧Sutton, Surrey, United Kingdom
Hacettepe University Faculty of Medicine ( Site 0498)
🇹🇷Ankara, Turkey
Gazi Universitesi Tip Fakultesi ( Site 0496)
🇹🇷Ankara, Turkey
University of California - San Francisco ( Site 0030)
🇺🇸San Francisco, California, United States
Northwest Georgia Oncology Centers PC ( Site 0045)
🇺🇸Marietta, Georgia, United States
Decatur Memorial Hospital ( Site 0056)
🇺🇸Decatur, Illinois, United States
Blue Ridge Cancer Care ( Site 0033)
🇺🇸Roanoke, Virginia, United States
Columbia University/Herbert Irving Cancer Center ( Site 0009)
🇺🇸New York, New York, United States
Winthrop University Hospital ( Site 0059)
🇺🇸Mineola, New York, United States
Laura and Isaac Perlmutter Cancer Center at NYU Langone Health ( Site 0038)
🇺🇸New York, New York, United States
Liverpool Hospital ( Site 0707)
🇦🇺Liverpool, New South Wales, Australia
Mid North Coast Cancer Institute ( Site 0708)
🇦🇺Port Macquarie, New South Wales, Australia
Grand Hopital de Charleroi ( Site 0206)
🇧🇪Charleroi, Hainaut, Belgium
UZ Gent ( Site 0203)
🇧🇪Gent, Oost-Vlaanderen, Belgium
Instituto COI de Pesquisa Educacao e Gestao ( Site 0606)
🇧🇷Rio de Janeiro, Brazil
Instituto do Cancer do Estado de Sao Paulo - ICESP ( Site 0607)
🇧🇷Sao Paulo, Brazil
A.C. Camargo Cancer Center ( Site 0600)
🇧🇷Sao Paulo, Brazil
IC La Serena Research ( Site 0630)
🇨🇱La Serena, Coquimbo, Chile
Fundacion Arturo Lopez Perez FALP ( Site 0623)
🇨🇱Santiago, Region M. De Santiago, Chile
Guangdong Provincial People s Hospital ( Site 0161)
🇨🇳Guangzhou, Guangdong, China
The Third Xiangya Hospital of Central South University ( Site 0157)
🇨🇳Changsha, Hainan, China
Fudan University Shanghai Cancer Center ( Site 0160)
🇨🇳Shanghai, Shanghai, China
Renji Hospital Shanghai Jiaotong University School of Medicine ( Site 0158)
🇨🇳Shanghai, Shanghai, China
Zhejiang Cancer Hospital ( Site 0134)
🇨🇳Hangzhou, Zhejiang, China
Centre Eugene Marquis ( Site 0242)
🇫🇷Rennes, Ille-et-Vilaine, France
Universitaetsklinikum Ulm ( Site 0267)
🇩🇪Ulm, Baden-Wurttemberg, Germany
Universitaetsklinikum Essen ( Site 0273)
🇩🇪Essen, Nordrhein-Westfalen, Germany
Universitaetsklinikum Aachen AOER ( Site 0275)
🇩🇪Aachen, Nordrhein-Westfalen, Germany
Staedtisches Klinikum Dresden ( Site 0272)
🇩🇪Dresden, Sachsen, Germany
Charite - Universtitatsmedizin Berlin CCM ( Site 0269)
🇩🇪Berlin, Germany
Universitaetsklinikum Hamburg-Eppendorf ( Site 0268)
🇩🇪Hamburg, Germany
Bon Secours Hospital ( Site 0526)
🇮🇪Cork, Ireland
Rambam Medical Center ( Site 0308)
🇮🇱Haifa, Israel
St Vincents University Hospital ( Site 0521)
🇮🇪Dublin, Ireland
Rabin Medical Center ( Site 0307)
🇮🇱Petah Tikva, Israel
Sourasky Medical Center ( Site 0306)
🇮🇱Tel Aviv, Israel
Kanagawa Cancer Center ( Site 0079)
🇯🇵Yokohama, Kanagawa, Japan
Osaka International Cancer Institute ( Site 0084)
🇯🇵Osaka, Japan
Seoul National University Bundang Hospital ( Site 0833)
🇰🇷Seongnam-si, Kyonggi-do, Korea, Republic of
Pantai Hospital Kuala Lumpur ( Site 0771)
🇲🇾Kuala Lumpur, Malaysia
Maastricht University Medical Centre ( Site 0347)
🇳🇱Maastricht, Limburg, Netherlands
AMC ( Site 0348)
🇳🇱Amsterdam, Noord-Holland, Netherlands
Erasmus University Medical Center ( Site 0352)
🇳🇱Rotterdam, Zuid-Holland, Netherlands
Hospital General Universitario Gregorio Maranon ( Site 0433)
🇪🇸Madrid, Spain
Hospital General Universitari Vall d Hebron ( Site 0432)
🇪🇸Barcelona, Spain
Taipei Veterans General Hospital ( Site 0861)
🇨🇳Taipei,, Taipei, Taiwan
Chang Gung Medical Foundation. Kaohsiung Branch ( Site 0865)
🇨🇳Kaohsiung, Taiwan
Hospital Regional Universitario Carlos Haya ( Site 0431)
🇪🇸Malaga, Spain
National Taiwan University Hospital ( Site 0860)
🇨🇳Taipei, Taiwan
Koo Foundation Sun Yat-Sen Cancer Center ( Site 0863)
🇨🇳Taipei, Taiwan
Ramathibodi Hospital. ( Site 0889)
🇹🇭Bangkok, Krung Thep Maha Nakhon, Thailand
Royal Free London NHS Foundation Trust ( Site 0520)
🇬🇧London, London, City Of, United Kingdom
Göztepe Prof. Dr. Süleyman Yalçın Şehir Hastanesi-oncology ( Site 0495)
🇹🇷Istanbul, Turkey
Izmir Medical Park Hospital Department of Medical Oncology ( Site 0502)
🇹🇷Izmir, Turkey
Istanbul Universitesi Cerrahpasa Tip Fakultesi ( Site 0506)
🇹🇷Istanbul, Turkey
Aberdeen Royal Infirmary ( Site 0529)
🇬🇧Aberdeen, Aberdeen City, United Kingdom
Royal Marsden Hospital ( Site 0536)
🇬🇧London, London, City Of, United Kingdom
Imperial College Healthcare NHS Trust - Hammersmith Hospital ( Site 0525)
🇬🇧London, London, City Of, United Kingdom
Belfast City Hospital ( Site 0517)
🇬🇧Belfast, United Kingdom
The Christie NHS Foundation Trust ( Site 0537)
🇬🇧Manchester, United Kingdom
Hospital Universitario HM Sanchinarro ( Site 0435)
🇪🇸Madrid, Spain
University of Alabama at Birmingham Comprehensive Cancer Ctr ( Site 0016)
🇺🇸Birmingham, Alabama, United States
University of Colorado Hospital ( Site 0011)
🇺🇸Aurora, Colorado, United States
Yale University ( Site 0053)
🇺🇸New Haven, Connecticut, United States
University of Oklahoma- Stephenson Oklahoma Cancer Center ( Site 0055)
🇺🇸Oklahoma City, Oklahoma, United States
Charleston Oncology ( Site 0042)
🇺🇸Charleston, South Carolina, United States
Queen Elizabeth Hospital. ( Site 0854)
🇭🇰Kowloon, Hong Kong
Queen Mary Hospital ( Site 0851)
🇭🇰Hong Kong, Hong Kong
Princess Margaret Hospital. ( Site 0856)
🇭🇰Hong Kong, Hong Kong
Prince of Wales Hospital ( Site 0855)
🇭🇰Hong Kong, Hong Kong
Pamela Youde Nethersole Eastern Hospital ( Site 0857)
🇭🇰Hong Kong, Hong Kong